Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sphingolipids as therapeutics.

Mark Kester1, Richard Kolesnick

  • 1Department of Pharmacology, Penn State University College of Medicine, Hershey, PA, USA. mxk38@psu.edu

Pharmacological Research
|April 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiosensitizing the SUMO stress response intensifies single-dose radiotherapy tumor cure.

JCI insight·2025
Same author

Acid sphingomyelinase inhibition induces cerebral angiogenesis post-ischemia/reperfusion in an oxidative stress-dependent way and promotes endothelial survival by regulating mitochondrial metabolism.

Cell death & disease·2024
Same author

Anti-Ceramide ScFv Prophylaxis for First Responders to a Limited Nuclear Attack.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology·2024
Same author

Pronecroptotic Therapy Using Ceramide Nanoliposomes Is Effective for Triple-Negative Breast Cancer Cells.

Cells·2024
Same author

Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes.

Blood advances·2024
Same author

MicroRNA-10a enrichment in factor VIIa-released endothelial extracellular vesicles: potential mechanisms.

Journal of thrombosis and haemostasis : JTH·2023

Sphingolipid metabolites, once known as second messengers, are now recognized for their therapeutic potential. Research is translating basic science discoveries into clinical applications for sphingolipid-based treatments.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Biophysics

Background:

  • The sphingolipid field has advanced significantly in the last decade.
  • Sphingomyelin pathway metabolites are identified as crucial second messengers.
  • Basic science research has elucidated the molecular biology and biophysics of these lipid-derived molecules.

Purpose of the Study:

  • To review the emerging concept of sphingolipid metabolites as therapeutics.
  • To highlight the clinical potential of manipulating sphingolipid pathways.
  • To consolidate knowledge from diverse scientific disciplines.

Main Methods:

  • Literature review of biochemistry, biophysics, molecular biology, and physiology of sphingolipids.
  • Analysis of publications detailing sphingolipid pathway research.

Related Experiment Videos

  • Synthesis of findings from multiple scientific disciplines.

    • Main Results:

    • Sphingolipid metabolites have demonstrated significant basic science relevance.
    • Translational research is actively exploring therapeutic applications.
    • The potential for clinical use of sphingolipid metabolites is increasingly evident.

    Conclusions:

    • Sphingolipid metabolites represent a promising area for therapeutic development.
    • Interdisciplinary collaboration is driving innovation in sphingolipid-based therapies.
    • Further research is warranted to fully realize the clinical potential of sphingolipids.